Business Description
DHG Pharmaceutical JSC
NAICS : 325412
ISIN : VN000000DHG0
Description
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotic, antifungal, and antiparasitic; analgesic and antipyretic; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.46 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | 1.09 | |||||
| Interest Coverage | 35.78 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.75 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | 11.4 | |||||
| 3-Year EPS without NRI Growth Rate | 12.7 | |||||
| 3-Year Book Growth Rate | 10.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -3.99 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.28 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.09 | |||||
| 9-Day RSI | 45.62 | |||||
| 14-Day RSI | 49.96 | |||||
| 6-1 Month Momentum % | -11.42 | |||||
| 12-1 Month Momentum % | -0.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.72 | |||||
| Quick Ratio | 1.95 | |||||
| Cash Ratio | 1.6 | |||||
| Days Inventory | 186.95 | |||||
| Days Sales Outstanding | 35.86 | |||||
| Days Payable | 30.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 7.09 | |||||
| Dividend Payout Ratio | 1.22 | |||||
| 3-Year Dividend Growth Rate | -7.9 | |||||
| Forward Dividend Yield % | 7.09 | |||||
| 5-Year Yield-on-Cost % | 14.74 | |||||
| Shareholder Yield % | 4.49 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.82 | |||||
| Operating Margin % | 17.53 | |||||
| Net Margin % | 16.75 | |||||
| FCF Margin % | 16.99 | |||||
| ROE % | 17.92 | |||||
| ROA % | 13.53 | |||||
| ROIC % | 25.99 | |||||
| ROC (Joel Greenblatt) % | 37.58 | |||||
| ROCE % | 20.26 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.19 | |||||
| Forward PE Ratio | 14.65 | |||||
| PE Ratio without NRI | 17.2 | |||||
| Shiller PE Ratio | 16.71 | |||||
| Price-to-Owner-Earnings | 14.27 | |||||
| PEG Ratio | 1.79 | |||||
| PS Ratio | 2.83 | |||||
| PB Ratio | 3.14 | |||||
| Price-to-Tangible-Book | 3.27 | |||||
| Price-to-Free-Cash-Flow | 16.7 | |||||
| Price-to-Operating-Cash-Flow | 14.02 | |||||
| EV-to-EBIT | 12.76 | |||||
| EV-to-Forward-EBIT | 11.4 | |||||
| EV-to-EBITDA | 11.45 | |||||
| EV-to-Forward-EBITDA | 10.6 | |||||
| EV-to-Revenue | 2.45 | |||||
| EV-to-Forward-Revenue | 2.43 | |||||
| EV-to-FCF | 15.24 | |||||
| Price-to-Projected-FCF | 1.55 | |||||
| Price-to-Median-PS-Value | 0.93 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.96 | |||||
| Price-to-Graham-Number | 1.58 | |||||
| Price-to-Net-Current-Asset-Value | 4.63 | |||||
| Price-to-Net-Cash | 13.93 | |||||
| Earnings Yield (Greenblatt) % | 7.84 | |||||
| FCF Yield % | 6.1 | |||||
| Forward Rate of Return (Yacktman) % | 12.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DHG Pharmaceutical JSC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚«) | 4,960,914.749 | ||
| EPS (TTM) (â‚«) | 6150.24 | ||
| Beta | 0 | ||
| Volatility % | 13.75 | ||
| 14-Day RSI | 49.96 | ||
| 14-Day ATR (â‚«) | 2150.221154 | ||
| 20-Day SMA (â‚«) | 106005 | ||
| 12-1 Month Momentum % | -0.69 | ||
| 52-Week Range (â‚«) | 98500 - 125900 | ||
| Shares Outstanding (Mil) | 130.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DHG Pharmaceutical JSC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DHG Pharmaceutical JSC Stock Events
| Event | Date | Price(â‚«) | ||
|---|---|---|---|---|
| No Event Data | ||||
DHG Pharmaceutical JSC Frequently Asked Questions
What is DHG Pharmaceutical JSC(STC:DHG)'s stock price today?
The current price of STC:DHG is â‚«105800.00. The 52 week high of STC:DHG is â‚«125900.00 and 52 week low is â‚«98500.00.
When is next earnings date of DHG Pharmaceutical JSC(STC:DHG)?
The next earnings date of DHG Pharmaceutical JSC(STC:DHG) is .
Does DHG Pharmaceutical JSC(STC:DHG) pay dividends? If so, how much?
The Dividend Yield %  of DHG Pharmaceutical JSC(STC:DHG) is 7.09% (As of Today), Highest Dividend Payout Ratio of DHG Pharmaceutical JSC(STC:DHG) was 1.22. The lowest was 0.25. And the median was 0.52. The  Forward Dividend Yield % of DHG Pharmaceutical JSC(STC:DHG) is 7.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers